Tagworks Pharmaceuticals develops a Click-to-Release chemistry platform designed to deliver effective and safe systemic therapies, including click-cleavable ADCs and immunomodulators. Its lead program, TGW101, is an antibody-drug conjugate targeting TAG72, a clinically validated pan-carcinoma target. The platform is protected by a broad patent estate and also enables off-target deactivation of radioimmunotherapies to improve therapeutic index. The company plans to use the new capital to advance TGW101 into the clinic and to expand its pipeline of click-cleavable therapies. Tagworks operates in the Netherlands and the U.S. and is led by CEO Marc Robillard. The company positions its Click-to-Release approach as a route to precision, on-target activation of therapies for severe diseases including cancer.

Total raised

$65M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2023